Sarepta Therapeutics
SRPT
148 hedge funds and large institutions have $661M invested in Sarepta Therapeutics in 2016 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 49 increasing their positions, 34 reducing their positions, and 20 closing their positions.
80% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 20
44% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 34
12% more funds holding
Funds holding: 132 → 148 (+16)
3% less capital invested
Capital invested by funds: $680M → $661M (-$19.4M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
38% less call options, than puts
Call options by funds: $270M | Put options by funds: $436M
Top Buyers
| 1 |
Jennison Associates
New York
|
+$19.4M |
| 2 |
State Street
Boston,
Massachusetts
|
+$11.6M |
| 3 |
Morgan Stanley
New York
|
+$9.67M |
| 4 |
Group One Trading
Chicago,
Illinois
|
+$9.41M |
| 5 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$9.12M |
Top Sellers
| 1 |
Citadel Advisors
Miami,
Florida
|
-$25.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$21.2M |
| 3 |
TCP
Tourbillon Capital Partners
New York
|
-$15.7M |
| 4 |
D.E. Shaw & Co
New York
|
-$13.9M |
| 5 |
PC
PointState Capital
New York
|
-$13.9M |
SRPT Hedge Fund Activity: Q2 2016 in Review
148 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Sarepta Therapeutics (SRPT) for Q2 2016, worth a combined $661M — down 2.9% from $680M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new SRPT positions and 20 closed out — a net gain of 16 holders — while 49 added to existing stakes and 34 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $19.4M. The largest seller was Citadel Advisors, cutting an estimated $25.1M.
- 148 institutional investors held Sarepta Therapeutics (SRPT) as of Q2 2016, up from 132 in Q1 2016.
- Funds reported $661M of Sarepta Therapeutics stock for Q2 2016, down 2.9% quarter-over-quarter.
- 36 funds opened new Sarepta Therapeutics positions in Q2 2016 and 20 closed out, a net change of +16 holders.
- The largest Sarepta Therapeutics buyer in Q2 2016 was Jennison Associates, an estimated $19.4M added.
- The largest Sarepta Therapeutics seller in Q2 2016 was Citadel Advisors, an estimated $25.1M sold.
Based on aggregated 13F filings for Q2 2016.